Developer docs
API playgroundTry for free, no card

Search company profiles

Arch Therapeutics

Full company profile

uuid00068s3

Namestring
Arch Therapeutics
Legal namestring
Arch Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Arch Therapeutics, Inc. is a publicly traded medical device company (OTCQB: ARTH) headquartered in Framingham, Massachusetts, that develops and commercializes wound care and biosurgical products based on a proprietary self-assembling peptide (SAP) platform technology. The technology, discovered at MIT by co-founder Dr. Rutledge Ellis-Behnke, uses synthetic peptides composed of naturally-occurring amino acids that, upon contact with ionic wound fluid, self-assemble into a nanofiber network mimicking the extracellular matrix. This forms an immediate physical barrier that provides hemostasis without pressure, cauterization, vasoconstriction, coagulation, or cross-linked adhesives, while serving as a scaffold to facilitate tissue repair. The company's primary commercial product is AC5 Advanced Wound System, marketed in the USA for chronic and acute wound care, with a parallel European product, AC5 Topical Hemostat, sold for hemostatic and sealant applications.

Short descriptiontext

Arch Therapeutics is a publicly traded medical device company that develops and sells the AC5 Advanced Wound System, a synthetic self-assembling peptide wound dressing for hospitals, wound care centers, and plastic surgery practices, plus AC5 Topical Hemostat in Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNatick, United States
HQ citystring
Natick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wound care products, hemostatic devices, self-assembling peptides, biosurgical products, medical device manufacturing
Industry4 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Wound Care and Hemostatic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1AC5 Advanced Wound System Sales
TypeOne Time License
Description

Direct product sales of AC5 Advanced Wound System (item number AC5-1001) available in the USA. The company sells directly to government and non-government customers through phone and email ordering channels.

archtherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1AC5 Advanced Wound System
Description

The company's primary commercial wound care product - a synthetic self-assembling peptide matrix that forms a nanofiber barrier on wounds to provide hemostasis and facilitate tissue healing. Available in the USA.

archtherapeutics.com
+1 more record
Core offering1 text field

Arch Therapeutics develops and commercializes self-assembling peptide (SAP) based wound care and biosurgical products. Its flagship product, AC5 Advanced Wound System, is a synthetic peptide matrix composed of naturally-occurring amino acids that forms a nanofiber network barrier on contact with wound ionic charge, providing hemostasis, modulating inflammation, and serving as a scaffold for tissue regeneration. The company also markets AC5 Topical Hemostat in Europe for hemostatic and sealant surgical applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 41% statistically significant improvement in median time to hemostasis (TTH) with AC5 vs control; TTH ≤30 seconds in AC5-treated wounds including patients on antiplatelet therapy
+2 more records
Product overview1 text field

Arch Therapeutics offers a unified platform of self-assembling peptide (SAP) products under the AC5 family. The core technology is a synthetic peptide matrix composed of naturally-occurring amino acids that self-assembles into a nanofiber network upon contact with ionic wound fluid. In the USA, this technology is marketed as the AC5 Advanced Wound System, an advanced wound dressing for chronic and acute wound care. In Europe, the same technology is sold as AC5 Topical Hemostat for hemostatic and sealant applications. Both products leverage the same proprietary self-assembling peptide platform to provide immediate barrier formation, hemostasis, and a microenvironment conducive to normal wound healing without requiring cold chain storage.

Product and service2 records
1AC5 Advanced Wound System
CategoryWound Care Dressings
Description

A synthetic self-assembling peptide-based advanced wound dressing (item number AC5-1001) that forms a nanofiber network upon contact with wound fluid, providing a physical barrier, modulating inflammation, and serving as a scaffold for tissue regeneration. Available in the USA for hospitals, wound care centers, plastic surgery practices, and vascular surgery departments managing chronic or acute wounds including venous leg ulcers, burn wounds, decubitus ulcers, and surgical wounds.

2AC5 Topical Hemostat
CategoryTopical Hemostats and Surgical Sealants
Description

The same synthetic self-assembling peptide technology as AC5 Advanced Wound System, marketed in Europe as a topical hemostat for promoting hemostasis and acting as a surgical sealant during interventional procedures, surgery, trauma, colonoscopy biopsy, and device implantation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Integra LifeSciences is a focused medical device company with a substantial wound care, regenerative tissue, and surgical franchise (e.g., Integra Dermal Regeneration Template). Comparable to Arch given the overlapping regenerative medicine and advanced wound care positioning, and similar mid-cap specialty medical device profile.

TypeBroad incumbent
Description

3M's Health Care segment provides advanced wound care products (e.g., 3M Tegaderm) sold globally to hospitals and clinics. Comparable to Arch given the shared advanced wound care customer base, though 3M is a much larger diversified incumbent.

TypeBroad incumbent
Description

BD offers hemostatic agents and surgical sealants through its surgery and biosciences portfolio, including products addressing bleeding control in the OR. Comparable to Arch's AC5 as both compete in surgical hemostasis with hospital customers and share a similar evidence-driven commercial model.

TypeDirect peer
Description

ConvaTec is a focused wound care and ostomy company with advanced wound dressings sold to hospitals, wound care clinics, and home health. Comparable to Arch's AC5 Advanced Wound System given the same advanced wound care customer base and clinical positioning.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device leader in advanced wound management (e.g., PICO, ALLEVYN) and surgical devices. Directly comparable to Arch's AC5 Advanced Wound System given its position in advanced wound dressings and chronic wound management sold to hospitals and wound care centers.

TypeDirect peer
Description

Organogenesis is a regenerative medicine company selling skin substitutes and advanced wound care products (e.g., Apligraf, Dermagraft) into wound care centers and hospitals. Closely comparable to Arch given the shared regenerative/biologic-matrix positioning in advanced wound healing and a similar specialty commercial footprint.

7Johnson & Johnson (Ethicon)
TypeBroad incumbent
Description

Ethicon, a J&J company, markets SURGICEL, EVICEL, and other hemostatic and sealant products used in operating rooms worldwide. Closely comparable to Arch's surgical hemostasis/barrier franchise given overlapping target customers (surgeons, hospitals) and product categories (topical hemostats and sealants).

TypeBroad incumbent
Description

Baxter is a major incumbent in hemostats and sealants through its FLOSEAL, TISSEEL, and COSEAL products used in surgical settings. Directly comparable to Arch's AC5 Topical Hemostat product given shared positioning in surgical hemostasis and tissue sealing across multiple surgical specialties.

9Collagen Solutions
TypeDirect peer
Description

Collagen Solutions/Collagen Matrix produces collagen-based medical devices including hemostats and wound care products. Directly comparable to Arch given the shared regenerative/biomaterial positioning for hemostasis and tissue repair in surgical and wound care applications.

TypeEmerging player
Description

ZymoGenetics historically developed topical recombinant thrombin (RECOTHROM) as a surgical hemostat. Comparable to Arch given the shared topical hemostat positioning for surgical bleeding control, and represents a comparable specialty hemostat strategic story (eventually acquired by a large pharma).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arch Therapeutics

Wound Care and Hemostatic Medical Devicesarchtherapeutics.com

Arch Therapeutics is a publicly traded medical device company that develops and sells the AC5 Advanced Wound System, a synthetic self-assembling peptide wound dressing for hospitals, wound care centers, and plastic surgery practices, plus AC5 Topical Hemostat in Europe.

What Arch Therapeutics does

Arch Therapeutics, Inc. is a publicly traded medical device company (OTCQB: ARTH) headquartered in Framingham, Massachusetts, that develops and commercializes wound care and biosurgical products based on a proprietary self-assembling peptide (SAP) platform technology. The technology, discovered at MIT by co-founder Dr. Rutledge Ellis-Behnke, uses synthetic peptides composed of naturally-occurring amino acids that, upon contact with ionic wound fluid, self-assemble into a nanofiber network mimicking the extracellular matrix. This forms an immediate physical barrier that provides hemostasis without pressure, cauterization, vasoconstriction, coagulation, or cross-linked adhesives, while serving as a scaffold to facilitate tissue repair. The company's primary commercial product is AC5 Advanced Wound System, marketed in the USA for chronic and acute wound care, with a parallel European product, AC5 Topical Hemostat, sold for hemostatic and sealant applications.

Arch Therapeutics firmographics

Firmographics
Name
Arch Therapeutics
Legal name
Arch Therapeutics, Inc.
Website
https://archtherapeutics.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Arch Therapeutics is a publicly traded medical device company that develops and sells the AC5 Advanced Wound System, a synthetic self-assembling peptide wound dressing for hospitals, wound care centers, and plastic surgery practices, plus AC5 Topical Hemostat in Europe.
Ownership category
akta.pro rank

Arch Therapeutics industry classification

Industry
Product category
Wound Care and Hemostatic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Wound care products
  • Hemostatic devices
  • Self-assembling peptides
  • Biosurgical products
  • Medical device manufacturing

Where Arch Therapeutics is headquartered

Location

Headquarters

HQ city
Natick
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Arch Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. AC5 Advanced Wound System Sales: Direct product sales of AC5 Advanced Wound System (item number AC5-1001) available in the USA. The company sells directly to government and non-government customers through phone and email ordering channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Arch Therapeutics product offering

Product offering

Core offering

Arch Therapeutics develops and commercializes self-assembling peptide (SAP) based wound care and biosurgical products. Its flagship product, AC5 Advanced Wound System, is a synthetic peptide matrix composed of naturally-occurring amino acids that forms a nanofiber network barrier on contact with wound ionic charge, providing hemostasis, modulating inflammation, and serving as a scaffold for tissue regeneration. The company also markets AC5 Topical Hemostat in Europe for hemostatic and sealant surgical applications.

Product overview

Arch Therapeutics offers a unified platform of self-assembling peptide (SAP) products under the AC5 family. The core technology is a synthetic peptide matrix composed of naturally-occurring amino acids that self-assembles into a nanofiber network upon contact with ionic wound fluid. In the USA, this technology is marketed as the AC5 Advanced Wound System, an advanced wound dressing for chronic and acute wound care. In Europe, the same technology is sold as AC5 Topical Hemostat for hemostatic and sealant applications. Both products leverage the same proprietary self-assembling peptide platform to provide immediate barrier formation, hemostasis, and a microenvironment conducive to normal wound healing without requiring cold chain storage.

Differentiator

Problem solved

Functional benefit

Brands

  • AC5 Advanced Wound System: The company's primary commercial wound care product - a synthetic self-assembling peptide matrix that forms a nanofiber barrier on wounds to provide hemostasis and facilitate tissue healing. Available in the USA.
  • AC5 Topical Hemostat

Products and services

  • AC5 Advanced Wound System A synthetic self-assembling peptide-based advanced wound dressing (item number AC5-1001) that forms a nanofiber network upon contact with wound fluid, providing a physical barrier, modulating inflammation, and serving as a scaffold for tissue regeneration. Available in the USA for hospitals, wound care centers, plastic surgery practices, and vascular surgery departments managing chronic or acute wounds including venous leg ulcers, burn wounds, decubitus ulcers, and surgical wounds.
  • AC5 Topical Hemostat The same synthetic self-assembling peptide technology as AC5 Advanced Wound System, marketed in Europe as a topical hemostat for promoting hemostasis and acting as a surgical sealant during interventional procedures, surgery, trauma, colonoscopy biopsy, and device implantation.

Quantifiable outcome

  • 41% statistically significant improvement in median time to hemostasis (TTH) with AC5 vs control; TTH ≤30 seconds in AC5-treated wounds including patients on antiplatelet therapy
  • +2 more outcomes

Companies that use Arch Therapeutics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Arch Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Arch Therapeutics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Arch Therapeutics competitors and assessment

Company assessment

Direct peers

  • Integra LifeSciences: Integra LifeSciences is a focused medical device company with a substantial wound care, regenerative tissue, and surgical franchise (e.g., Integra Dermal Regeneration Template). Comparable to Arch given the overlapping regenerative medicine and advanced wound care positioning, and similar mid-cap specialty medical device profile.
  • ConvaTec: ConvaTec is a focused wound care and ostomy company with advanced wound dressings sold to hospitals, wound care clinics, and home health. Comparable to Arch's AC5 Advanced Wound System given the same advanced wound care customer base and clinical positioning.
  • Organogenesis: Organogenesis is a regenerative medicine company selling skin substitutes and advanced wound care products (e.g., Apligraf, Dermagraft) into wound care centers and hospitals. Closely comparable to Arch given the shared regenerative/biologic-matrix positioning in advanced wound healing and a similar specialty commercial footprint.
  • Collagen Solutions: Collagen Solutions/Collagen Matrix produces collagen-based medical devices including hemostats and wound care products. Directly comparable to Arch given the shared regenerative/biomaterial positioning for hemostasis and tissue repair in surgical and wound care applications.

Broad incumbents

  • 3M Health Care: 3M's Health Care segment provides advanced wound care products (e.g., 3M Tegaderm) sold globally to hospitals and clinics. Comparable to Arch given the shared advanced wound care customer base, though 3M is a much larger diversified incumbent.
  • BD (Becton Dickinson): BD offers hemostatic agents and surgical sealants through its surgery and biosciences portfolio, including products addressing bleeding control in the OR. Comparable to Arch's AC5 as both compete in surgical hemostasis with hospital customers and share a similar evidence-driven commercial model.
  • Smith+Nephew: Smith+Nephew is a global medical device leader in advanced wound management (e.g., PICO, ALLEVYN) and surgical devices. Directly comparable to Arch's AC5 Advanced Wound System given its position in advanced wound dressings and chronic wound management sold to hospitals and wound care centers.
  • Johnson & Johnson (Ethicon): Ethicon, a J&J company, markets SURGICEL, EVICEL, and other hemostatic and sealant products used in operating rooms worldwide. Closely comparable to Arch's surgical hemostasis/barrier franchise given overlapping target customers (surgeons, hospitals) and product categories (topical hemostats and sealants).
  • Baxter International: Baxter is a major incumbent in hemostats and sealants through its FLOSEAL, TISSEEL, and COSEAL products used in surgical settings. Directly comparable to Arch's AC5 Topical Hemostat product given shared positioning in surgical hemostasis and tissue sealing across multiple surgical specialties.

Emerging players

  • ZymoGenetics (acquired by Bristol-Myers Squibb): ZymoGenetics historically developed topical recombinant thrombin (RECOTHROM) as a surgical hemostat. Comparable to Arch given the shared topical hemostat positioning for surgical bleeding control, and represents a comparable specialty hemostat strategic story (eventually acquired by a large pharma).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Arch Therapeutics social profiles

Digital presence

Arch Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arch Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Arch Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arch Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arch Therapeutics

What does Arch Therapeutics do?

Arch Therapeutics develops and commercializes self-assembling peptide (SAP) based wound care and biosurgical products. Its flagship product, AC5 Advanced Wound System, is a synthetic peptide matrix composed of naturally-occurring amino acids that forms a nanofiber network barrier on contact with wound ionic charge, providing hemostasis, modulating inflammation, and serving as a scaffold for tissue regeneration. The company also markets AC5 Topical Hemostat in Europe for hemostatic and sealant surgical applications.

Is Arch Therapeutics a public or private company?

Arch Therapeutics is a public company. It is classified as public and is currently operating.

When was Arch Therapeutics founded?

Arch Therapeutics was founded in 2011. It employs 11 to 50 people.

Where is Arch Therapeutics based?

Arch Therapeutics is headquartered in Natick, United States, in the North America region.

How does Arch Therapeutics make money?

One revenue line is on record: AC5 Advanced Wound System Sales.

Who are Arch Therapeutics's main competitors?

Direct peers on record are Integra LifeSciences, ConvaTec, Organogenesis and Collagen Solutions. Broad incumbents are 3M Health Care, BD (Becton Dickinson), Smith+Nephew, Johnson & Johnson (Ethicon) and Baxter International. ZymoGenetics (acquired by Bristol-Myers Squibb) is listed as an emerging player.

Does Arch Therapeutics have an API?

No public API is recorded for Arch Therapeutics.

What industry is Arch Therapeutics in?

Arch Therapeutics's product category is Wound Care and Hemostatic Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportAnalyzing Arch Therapeutics (OTCMKTS:ARTH) & KORU Medical Systems (NASDAQ:KRMD)KORU Medical Systems and Arch Therapeutics were compared based on various financial metrics, with KORU Medical Systems generally outperforming Arch Therapeutics in key areas such as valuation, profitability, and analyst ratings. KORU Medical Systems has a consensus price target of $7.00, indicating a potential upside of 96.63%, while Arch Therapeutics reported significantly negative metrics. The analysis suggests that KORU Medical Systems is viewed more favorably by analysts compared to Arch Therapeutics.Defense WorldInterpace Biosciences (OTCMKTS:IDXG) versus Arch Therapeutics (OTCMKTS:ARTH) Head-To-Head ContrastThis article presents a head-to-head financial comparison between Interpace Biosciences and Arch Therapeutics, two OTCMKTS-traded companies, across nine metrics including risk/volatility, valuation, earnings, and profitability. Interpace Biosciences outperforms Arch Therapeutics on seven of the nine factors compared, reporting $38.73 million in revenue versus $80,000 for Arch Therapeutics, and a 63.46% net margin compared to Arch's -8,257.70% net margin. The comparison highlights Interpace as the more affordable stock based on its lower price-to-earnings ratio and stronger financial position.The Globe and MailArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)Arch Therapeutics will present its AC5 Advanced Wound System at the 2024 SAWC Fall meeting in Las Vegas, October 2-5. The company will demonstrate the product and present clinical cases, including a pilot study on healing time and cost savings for complicated post-operative wounds.GlobeNewswireArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)Arch Therapeutics will present its AC5 Advanced Wound System at the 2024 SAWC Fall meeting in Las Vegas, October 2-5. The company will demonstrate the self-assembling wound care product and present clinical cases, including a pilot study on healing time and cost savings for complicated post-operative wounds.Business InsiderArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)Arch Therapeutics will present its AC5 Advanced Wound System at the 2024 SAWC Fall Meeting in Las Vegas, Oct 2-5. The company will demonstrate the FDA-cleared product and present clinical cases, including a pilot study on healing time and cost savings for complicated post-operative wounds.Worcester Business JournalFramingham life sciences firm raises $2.6M ahead of planned uplistingArch Therapeutics, a Framingham-based life sciences firm, raised $2.6 million in bridge funding to support its planned uplisting from the OTCQB exchange to a major national exchange such as Nasdaq or NYSE. The company aims to leverage these resources and recent regulatory approvals, including a unique billing code for its AC5 Advanced Wound System, to drive revenue growth.GlobeNewswireDedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In EffectArch Therapeutics announced that CMS assigned HCPCS code A2020 to its AC5 Advanced Wound System, effective April 1, 2023. The code is expected to improve reimbursement for the product in outpatient settings, including doctors' offices and wound care clinics. The company stated the code is a key commercialization milestone, though it does not guarantee coverage.GlobeNewswireArch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government FacilitiesArch Therapeutics announced it will add about 15 independent commission-based sales representatives by end of Q1 2023 to support AC5 Advanced Wound System in federal government facilities, including VA, IHS, DOD, and MTF. The expansion aims to optimize sales in new and existing regions, with early data showing positive results in challenging wounds.BioSpaceArch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound SystemArch Therapeutics launched a multi-site clinical study for its AC5 Advanced Wound System, expected to enroll up to 60 patients at six sites with a primary endpoint of wound closure. The study aims to accelerate payor adoption and differentiate AC5's benefits for challenging wounds.citybizArch Therapeutics Raises Approximately $3.5 Million in Convertible Note FinancingArch Therapeutics completed a private placement of senior secured convertible notes, raising approximately $3.5 million from institutional and accredited investors. The funds are designated to support an expected uplisting to a national exchange by the first quarter of 2023 and to advance the company's commercialization plan for its wound care products.